BioSpace reviews some recently published scientific studies, including researchers with the University of Colorado Anschutz Medical Campus releasing a new study calling attention to the emergence of mosquito-borne viral outbreaks in West Africa.

Amarin Corp. provided an update, noting that the company is increasing revenue guidance for 2019 and is planning to expand the sales force for Vascepa due to faster-than-expected growth.

Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. announced that Waylivra received conditional marketing authorization from the European Commission as the only therapy for FCS.

Ultragenyx shares were down after announcing the Phase III drug candidate UX007 failed to hit the mark as a treatment for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) who are experiencing disabling paroxysmal movement disorders.

In Amarin’s REDUCE-IT clinical trial of 8,179 statin-treated adults with increased risk of cardiovascular problems, the drug showed a 25 percent relative risk reduction in major adverse cardiovascular events compared to placebo.